Count Eli Lilly & Co. as a believer in the future of private-pay in the pharma market: prescription-only medicines that fall outside the control of managed care gatekeepers in the US.
Lilly is paying $2.1 billion to buy out Icos Corp. , its joint venture partner in the erectile dysfunction category,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?